Aprea Therapeutics' Promising Cancer Drug Candidate Warrants Buy Rating

TipRanksApr 12 23:35

Optimistic Outlook for Aprea Therapeutics' Oncology Pipeline: A Comprehensive Buy Rating Analysis

TipRanksApr 11 18:26

Aprea Therapeutics Announces Presentations on Its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Aprea Therapeutics, Inc. (Nasdaq: APRE) today released details about four poster presentations at the ongoing American Association of Cancer Research (AACR) Annual Meeting, taking place April 5 to 10, 2024 in San Diego, CA.

GlobeNewswireApr 11 00:00

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 85.5% to $4.86 during Thursday's pre-market session. The market value of their outstanding shares is at $800.0 million. Candel Therapeutics (NASDAQ

BenzingaApr 4 20:09

Aprea Therapeutics Files to Sell 4.39M Shares of Common Stock for Holders

Seeking AlphaApr 4 04:30

Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating

TipRanksMar 28 04:05